Repurposing the FDA-Approved Pinworm Drug Pyrvinium as a Novel Chemotherapeutic Agent for Intestinal Polyposis

Mutations in the WNT-pathway regulator ADENOMATOUS POLYPOSIS COLI (APC) promote aberrant activation of the WNT pathway that is responsible for APC-associated diseases such as Familial Adenomatous Polyposis (FAP) and 85% of spontaneous colorectal cancers (CRC). FAP is characterized by multiple intestinal adenomas, which inexorably result in CRC. Surprisingly, given their common occurrence, there are few effective chemotherapeutic drugs for FAP. Here we show that the FDA-approved, anti-helminthic drug Pyrvinium attenuates the growth of WNT-dependent CRC cells and does so via activation of CK1α. Furthermore, we show that Pyrvinium can function as an in vivo inhibitor of WNT-signaling and polyposis in a mouse model of FAP: APCmin mice. Oral administration of Pyrvinium, a CK1α agonist, attenuated the levels of WNT-driven biomarkers and inhibited adenoma formation in APCmin mice. Considering its well-documented safe use for treating enterobiasis in humans, our findings suggest that Pyrvinium could be repurposed for the clinical treatment of APC-associated polyposes.

[1]  M. Bienz,et al.  LEF1 and B9L shield β-catenin from inactivation by Axin, desensitizing colorectal cancer cells to tankyrase inhibitors. , 2014, Cancer research.

[2]  R. Lothe,et al.  Epigenetic and genetic features of 24 colon cancer cell lines , 2013, Oncogenesis.

[3]  C. Girardi,et al.  Pyrvinium pamoate does not activate protein kinase CK1, but promotes Akt/PKB down-regulation and GSK3 activation. , 2013, The Biochemical journal.

[4]  D. Bishop,et al.  A Randomized Placebo-Controlled Prevention Trial of Aspirin and/or Resistant Starch in Young People with Familial Adenomatous Polyposis , 2011, Cancer Prevention Research.

[5]  Steffen Jung,et al.  CKIα ablation highlights a critical role for p53 in invasiveness control , 2011, Nature.

[6]  Ethan Lee,et al.  Pyrvinium, a Potent Small Molecule Wnt Inhibitor, Promotes Wound Repair and Post-MI Cardiac Remodeling , 2010, PloS one.

[7]  Bruce J. Melancon,et al.  Small-molecule inhibition of Wnt signaling through activation of casein kinase 1α. , 2010, Nature chemical biology.

[8]  S. Kaesler,et al.  Suppression of casein kinase 1alpha in melanoma cells induces a switch in beta-catenin signaling to promote metastasis. , 2010, Cancer research.

[9]  Yingjie Yu,et al.  The Wnt/β-catenin pathway regulates growth and maintenance of colonospheres , 2010, Molecular Cancer.

[10]  J. Dering,et al.  Cyclin D1 is a direct target of JAG1-mediated Notch signaling in breast cancer , 2010, Breast Cancer Research and Treatment.

[11]  Xiangshan Fan,et al.  Expression of Lgr5 in human colorectal carcinogenesis and its potential correlation with β-catenin , 2010, International Journal of Colorectal Disease.

[12]  Lingyi Chen,et al.  A genomewide study identifies the Wnt signaling pathway as a major target of p53 in murine embryonic stem cells , 2009, Proceedings of the National Academy of Sciences.

[13]  Timothy H. Davis,et al.  Pyrvinium Targets the Unfolded Protein Response to Hypoglycemia and Its Anti-Tumor Activity Is Enhanced by Combination Therapy , 2008, PloS one.

[14]  H. Clevers,et al.  Identification of stem cells in small intestine and colon by marker gene Lgr5 , 2007, Nature.

[15]  K. Sugano,et al.  Differential gene expression between flat adenoma and normal mucosa in the colon in a microarray analysis , 2006, Journal of Gastroenterology.

[16]  P. Darcy,et al.  Colon epithelial cell differentiation is inhibited by constitutive c-myb expression or mutant APC plus activated RAS. , 2005, DNA and cell biology.

[17]  C. Rao,et al.  NSAIDs and chemoprevention. , 2004, Current cancer drug targets.

[18]  F. Castellino,et al.  Transcriptional profiling of the transition from normal intestinal epithelia to adenomas and carcinomas in the APCMin/+ mouse. , 2003, Physiological genomics.

[19]  C. Lindley,et al.  Use of NSAIDs for the Chemoprevention of Colorectal Cancer , 2003, The Annals of pharmacotherapy.

[20]  P. Schirmacher,et al.  Beta‐catenin accumulation in the progression of human hepatocarcinogenesis correlates with loss of E‐cadherin and accumulation of p53, but not with expression of conventional WNT‐1 target genes , 2003, The Journal of pathology.

[21]  G. Piazza,et al.  Sulindac metabolites induce caspase- and proteasome-dependent degradation of beta-catenin protein in human colon cancer cells. , 2003, Molecular cancer therapeutics.

[22]  K. Kinzler,et al.  Targeted inactivation of CTNNB1 reveals unexpected effects of β-catenin mutation , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[23]  Hans Clevers,et al.  Wnt Signaling Controls the Phosphorylation Status of β-Catenin* , 2002, The Journal of Biological Chemistry.

[24]  P. Catalano,et al.  c-myc/p53 interaction determines sensitivity of human colon carcinoma cells to 5-fluorouracil in vitro and in vivo. , 2001, Cancer research.

[25]  D. Leung,et al.  The enigma of desmoid tumors. , 1999, Annals of surgery.

[26]  Bruce A. Yankner,et al.  β-Trcp couples β-catenin phosphorylation-degradation and regulates Xenopus axis formation , 1999 .

[27]  Hideki Yamamoto,et al.  Phosphorylation of Axin, a Wnt Signal Negative Regulator, by Glycogen Synthase Kinase-3β Regulates Its Stability* , 1999, The Journal of Biological Chemistry.

[28]  M. Bertagnolli,et al.  Aspirin prevents tumors in a murine model of familial adenomatous polyposis. , 1998, Surgery.

[29]  M. Wallace,et al.  Upper gastrointestinal disease in patients with familial adenomatous polyposis , 1998, The British journal of surgery.

[30]  S. Baba.  [Molecular biological background of FAP and HNPCC, and treatment strategies of both diseases depend upon genetic information]. , 1998, Nihon Geka Gakkai zasshi.

[31]  Paul Polakis,et al.  Downregulation of β-catenin by human Axin and its association with the APC tumor suppressor, β-catenin and GSK3β , 1998, Current Biology.

[32]  Stephen W. Byers,et al.  Serine Phosphorylation-regulated Ubiquitination and Degradation of β-Catenin* , 1997, The Journal of Biological Chemistry.

[33]  G. Corner,et al.  Low-level c-myc amplification in human colonic carcinoma cell lines and tumors: a frequent, p53-independent mutation associated with improved outcome in a randomized multi-institutional trial. , 1997, Cancer research.

[34]  R. Moon,et al.  Signal transduction through beta-catenin and specification of cell fate during embryogenesis. , 1996, Genes & development.

[35]  K. Ishikawa,et al.  Mutations of p53, E-cadherin, alpha- and beta-catenin genes and tyrosine phosphorylation of beta-catenin in human gastric carcinomas. , 1996, International journal of oncology.

[36]  J. Church,et al.  Pouch polyposis after ileal pouch-anal anastomosis for familial adenomatous polyposis , 1996, Diseases of the colon and rectum.

[37]  M. Dunlop,et al.  Molecular genetic basis of colorectal cancer susceptibility , 1996, The British journal of surgery.

[38]  G. Orangio,et al.  Surgical options for familial adenomatous polyposis. , 1995, Seminars in surgical oncology.

[39]  G. Morgan.  NSAIDs and the chemoprevention of colon and oesophageal cancer. , 1995, Gut.

[40]  F. Masiarz,et al.  Association of the APC gene product with beta-catenin. , 1993, Science.

[41]  G. Thomas,et al.  Alleles of the APC gene: An attenuated form of familial polyposis , 1993, Cell.

[42]  J. Villalobos,et al.  [Molecular genetics of colorectal cancer and carcinogenesis]. , 1993, Revista de investigacion clinica; organo del Hospital de Enfermedades de la Nutricion.

[43]  M. Robertson,et al.  Mutational analysis of patients with adenomatous polyposis: identical inactivating mutations in unrelated individuals. , 1993, American journal of human genetics.

[44]  B. Vogelstein,et al.  Mutations of the APC (adenomatous polyposis coli) gene in FAP (familial polyposis coli) patients and in sporadic colorectal tumors. , 1992, The Tohoku journal of experimental medicine.

[45]  S. Altschul,et al.  Identification of FAP locus genes from chromosome 5q21. , 1991, Science.

[46]  H. Pitot,et al.  A dominant mutation that predisposes to multiple intestinal neoplasia in the mouse. , 1990, Science.

[47]  D. Gerlier,et al.  Use of MTT colorimetric assay to measure cell activation. , 1986, Journal of immunological methods.

[48]  M. Goldberg.  Pyrvinium pamoate lacks in vivo genotoxicity in the colon. , 1984, Toxicology and applied pharmacology.

[49]  F. A. de la Iglesia,et al.  Absence of in vitro genotoxicity of pyrvinium pamoate in sister-chromatid exchange, chromosome aberration, and HGPRT-locus mutation bioassays. , 1982, Journal of toxicology and environmental health.

[50]  J. Goulet,et al.  Absorption of pyrvinium pamoate , 1976, Clinical pharmacology and therapeutics.

[51]  Thompson Pe,et al.  Effects of pyrvinium pamoate in the ration or drinking water of mice against pinworms Syphacia obvelata and Aspiculuris tetraptera. , 1968 .

[52]  Bandyopadhyay Ak,et al.  Multiple dose therapy with pyrvinium pamoate in enterobiasis. , 1966 .

[53]  J. Alao,et al.  Molecular Cancer BioMed Central Review The regulation of cyclin D1 degradation: roles in cancer development and the potential for therapeutic invention , 2007 .

[54]  J. Haveman,et al.  Clonogenic assay of cells in vitro , 2006, Nature Protocols.

[55]  K. Kinzler,et al.  Targeted inactivation of CTNNB1 reveals unexpected effects of beta-catenin mutation. , 2002, Proceedings of the National Academy of Sciences of the United States of America.

[56]  J. Alexander,et al.  Identification and quantification of aberrant crypt foci in the colon of Min mice--a murine model of familial adenomatous polyposis. , 2000, Scandinavian journal of gastroenterology.

[57]  B. Yankner,et al.  beta-Trcp couples beta-catenin phosphorylation-degradation and regulates Xenopus axis formation. , 1999, Proceedings of the National Academy of Sciences of the United States of America.

[58]  B. Rigas,et al.  Role of diet and NSAIDs in the chemoprevention of colorectal cancer. , 1999, Journal of the Association for Academic Minority Physicians : the official publication of the Association for Academic Minority Physicians.

[59]  F. McCormick,et al.  Beta-catenin regulates expression of cyclin D1 in colon carcinoma cells. , 1999, Nature.

[60]  R. Phillips,et al.  Preventative strategies for periampullary tumours in FAP. , 1999, Annals of oncology : official journal of the European Society for Medical Oncology.

[61]  P. Polakis,et al.  Downregulation of beta-catenin by human Axin and its association with the APC tumor suppressor, beta-catenin and GSK3 beta. , 1998, Current biology : CB.

[62]  S. Byers,et al.  Serine phosphorylation-regulated ubiquitination and degradation of beta-catenin. , 1997, The Journal of biological chemistry.

[63]  K. Kinzler,et al.  Mutations of the adenomatous polyposis coli gene in familial polyposis coli patients and sporadic colorectal tumors. , 1991, Princess Takamatsu symposia.

[64]  D. Jagelman,et al.  Choice of operation in familial adenomatous polyposis , 1991, World journal of surgery.

[65]  L. S. Blair,et al.  Effects of pyrvinium pamoate in the ration or drinking water of mice against pinworms Syphacia obvelata and Aspiculuris tetraptera. , 1968, Laboratory animal care.

[66]  A. Chowdhury,et al.  Multiple dose therapy with pyrvinium pamoate in enterobiasis. , 1966, Bulletin of the Calcutta School of Tropical Medicine.